CD14 and coronary artery disorder: Therefore, we speculate that there may exist other regulatory mechanisms influencing the DNA methylation status of MCP1 promoter in CD14+ monocytes of CAD patients, which lead to no significant difference in DNA methylation level of MCP1 promoter between CAD patients and non-CAD patients.